Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia
Status:
Not yet recruiting
Trial end date:
2025-10-10
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of Venetoclax plus IM2 regimen for replapsed and
refractory T lymphoblastic lymphoma/leukemia. Dosage of Venetoclax:100mg/d-400mg/d(dose
adjustment when concomitant used with CYP3A inhibitor) for 1-28 days (at least 7 days); IM2
regimen: Ifosfamide 1-1.5g/m2/d for 5 days; Mitoxantrone 6-8g/m2/d for 3 days( or Liposome
mitoxantrone 20mg/m2 d1 or Idarubicin 6-8mg/m2/d for 3 days) ;methotrexate 1-1.5g/m2/d for 1
day;
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine